Resolve Therapeutics, LLC is a pioneering brand that specializes in the development of safe and targeted therapies for patients with autoimmune diseases. Their primary focus is on providing effective treatments for individuals who have been underserved in this area. Resolve Therapeutics has a lead program called RSLV-132, which is specifically designed to prevent chronic, systemic inflammation and its associated symptoms and organ damage.

This first-in-class RNase-Fc fusion protein is being developed to address the needs of patients with lupus and Sjögren’s syndrome. The company has successfully completed a Phase 2a study in lupus and is set to begin a Phase 3 study in Sjögren’s syndrome in 2022. The management team at Resolve Therapeutics is led by James Posada, Ph.

D., MBA, who brings extensive experience in the field of signal transduction and drug discovery. With a team committed to excellence, Resolve Therapeutics is at the forefront of developing groundbreaking solutions to meet the therapeutic needs of patients with autoimmune diseases